Vitrolife Group launches SEK 500 million share repurchase programme
The Board of Directors of Vitrolife AB (publ) ("Vitrolife Group") has today, based on the authorisation granted by the Annual General Meeting held on 5 May 2026, resolved to launch a share repurchase programme in a maximum amount of SEK 500 million during the period from 17 July 2026 up until the next Annual General Meeting.
The objective of the share repurchase programme is to optimise the company's capital structure and thus create increased value for the shareholders.
Acquisitions of own shares shall be made in accordance with Nasdaq Stockholm's Rulebook for Issuers during the period from 17 July 2026 up until the Annual General Meeting 2027. The maximum amount for which shares may be acquired may not exceed SEK 500 million. The maximum number of shares that may be acquired is such that Vitrolife Group's holding of own shares at any time does not exceed 10 per cent of the total number of shares in the company. Acquisitions shall be made in accordance with the price limitations set out in Nasdaq Stockholm's Rulebook for Issuers, which states that shares may not be purchased at a price higher than the higher of the price of the last independent trade and the highest current independent purchase bid on Nasdaq Stockholm. Acquisitions may not be made at a price lower than the lowest price at which an independent purchase can be made. The shares shall be paid in cash.
As of the date of this press release, the total number of shares in the company is 135,447,190. As of the date of this press release, Vitrolife Group holds 24,568 own shares in treasury.
The share repurchase will be carried out in addition to the ordinary cash dividend of SEK 1.10 per share for the 2025 financial year, as resolved by the Annual General Meeting on 5 May 2026. The company’s dividend policy, under which 30–50% of net income over time is to be distributed to shareholders, remains unchanged.
Completed acquisitions will be reported in accordance with applicable rules.
Contact:
Pär Ihrskog, CFO
e-mail: investors@vitrolife.com
phone: +46 (0) 31 721 80 00
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
About Us
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden.
Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
This information is information that Vitrolife is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-15 18:30 CEST.